Edwards Lifesciences (EW)

The company is best known for heart valve replacement and repair technologies. Its portfolio includes surgical tissue valves as well as transcatheter aortic valve replacement systems, a category that has transformed treatment for many patients with aortic stenosis who may be at elevated risk from open-heart surgery. Edwards also develops transcatheter mitral and tricuspid therapies, areas that address complex valve disorders and remain important long-term growth markets in structural heart care.

Edwards operates in a highly regulated and research-intensive segment of healthcare. Product performance, clinical evidence, physician training, reimbursement, and approvals from regulators such as the US Food and Drug Administration are central to its competitive position. The company sells to hospitals and healthcare systems worldwide, with a substantial share of revenue generated outside the United States.

For investors, Edwards Lifesciences represents exposure to specialised cardiovascular devices rather than broad healthcare services or pharmaceuticals. Its market position is shaped by demographic demand from ageing populations, the adoption of minimally invasive procedures, and competition from other large medical device manufacturers. The company’s distinctive focus on advanced heart valve disease gives it a narrower but deeply entrenched role in global medtech.